Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study

Diabetes Obes Metab. 2024 Jun;26(6):2513-2516. doi: 10.1111/dom.15552. Epub 2024 Mar 18.

Authors

Chenyang Shi¹, Yijiong Tan¹, Shanshan Hu¹, Yingyi Qin², Yuanjun Tang¹, Yufan Wang³, Guorong Fan¹

Affiliations

¹ Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.
² Department of Military Health Statistics, Naval Medical University, Shanghai, China.
³ Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.

PMID: 38497231
DOI: 10.1111/dom.15552

No abstract available

Publication types

Letter
Observational Study
Research Support, Non-U.S. Gov't
Comparative Study

MeSH terms

Aged
Blood Glucose / drug effects
Blood Glucose / metabolism
Diabetes Mellitus, Type 2* / blood
Diabetes Mellitus, Type 2* / drug therapy
Drug Administration Schedule
Female
Glucagon-Like Peptides* / administration & dosage
Glucagon-Like Peptides* / adverse effects
Glucagon-Like Peptides* / therapeutic use
Glycated Hemoglobin / analysis
Glycated Hemoglobin / drug effects
Glycated Hemoglobin / metabolism
Humans
Hypoglycemic Agents* / administration & dosage
Hypoglycemic Agents* / adverse effects
Hypoglycemic Agents* / therapeutic use
Injections, Subcutaneous
Male
Middle Aged
Product Surveillance, Postmarketing
Retrospective Studies
Treatment Outcome

Substances

semaglutide
Hypoglycemic Agents
Glucagon-Like Peptides
Blood Glucose
Glycated Hemoglobin

Grants and funding

SHYXH-ZP-2021-013/Shanghai Pharmaceutical Association of Clinical Comprehensive Evaluation of Drugs and Research Project on Drug Treatment Pathways